Treatment of Left Main Coronary Trifurcation Lesions with the Paclitaxel Drug-Eluting Stent: Mid-Term Outcomes from a Tertiary Medical Center
|
|
- Leslie Matthews
- 5 years ago
- Views:
Transcription
1 Original Contribution Treatment of Left Main Coronary Trifurcation Lesions with the Paclitaxel Drug-Eluting Stent: Mid-Term Outcomes from a Tertiary Medical Center Nicolas W. Shammas, MD, MS, Gail A. Shammas, BS, RN, Michael Jerin, PhD, Anup Parikh, Katherine Coin, Eric Dippel, MD, Peter Sharis, MD, Jon Robken, MD ABSTRACT: Background. Left main trifurcating coronary artery disease (LMTCAD) is a complex and challenging anatomy to treat percutaneously. We report on the immediate- and mid-term outcomes of 52 consecutive patients with LMTCAD treated with the Taxus paclitaxel-eluting stent (PES) (Boston Scientific Corp., Natick, Mass.) in our center over a period of 2 years. Methods. All patients (n = 52) who underwent LMTCAD at our center in and treated with the PES form the basis of this report. Demographic, clinical, procedural and in-hospital outcome variables were reviewed. Angiograms were analyzed by an operator blinded to the patients history. Mid-term follow up was achieved from medical records and/or phone calls. The primary endpoint of the study was either cardiac death, nonfatal myocardial infarction or target lesion revascularization (TLR) on follow up. Follow up was achieved in 47/51 patients (92.2%) at a mean of ± days. Patients were classified as Type A (30.8%) disease involving the LM and origin of branches, or Type B (69.2%) disease involving the origin of the trifurcation branches only, but not the LM artery. All patients were treated with kissing balloon after stenting. Descriptive analysis was performed on all variables with mean ± standard deviation for continuous variables and percentages describing dichotomous variables. Univariate and logistic regression analyses were performed to determine the predictors of the primary endpoint. Results. The mean patient age was 67.6 ± 12.7 years. The LM artery was unprotected in 88.5% of cases. On follow up, the primary endpoint was met in 34% of patients. TLR occurred in 31.9% of patients, and target vessel revascularization (TVR) in 40.4%. One patient had cardiac death (2.1%) 5 months after the index procedure, possibly related to acute stent thrombosis. By univariate analysis, Type A lesions (vs. type B; p = 0.02) and the placement of a greater number of stents (p = 0.044) correlated with a higher event rate. Logistic regression analysis showed that Type A lesions are the only predictors of the combined endpoint (p = 0.011). Conclusion. LM trifurcation stenting carries an overall high rate of adverse events, mostly driven by a high TLR rate. Type A lesions and the number of stents placed predicted a higher combined endpoint of death, nonfatal MI and TLR. By logistic regression analysis, Type A lesions are the only independent predictors of the primary outcome. Key words: Trifurcation stent, left main, paclitaxel-eluting stent, thrombosis J INVASIVE CARDIOL 2009;21: From the Midwest Cardiovascular Research Foundation (MCRF), Davenport, Iowa. The authors report no conflicts of interest regarding the content herein. Supported by the Nicolas and Gail Shammas Research Fund at MCRF. Manuscript submitted January 26, 2009, provisional acceptance given March 2, 2009, final version accepted March 30, Address for correspondence: Nicolas W. Shammas, MD, MS, Genesis Heart Institute, Cardiovascular Medicine, P.C., 1236 E. Rusholme, Davenport, IA shammas@mchsi.com Left main (LM) trifurcation coronary stenting is a challenging and complex percutaneous procedure that has been reported in small series and case reports. 1 9 A higher adverse event rate was described in these patients on long-term follow up. In a series of 20 patients treated with Taxus paclitaxel-eluting stent (PES) (Boston Scientific Corp., Natick, Massachusetts), we previously reported a combined endpoint of death, acute stent thrombosis and target lesion revascularization (TLR) of 29.4%. 6 Furuichi et al 8 later reported a TLR rate of 20% in their series of 15 trifurcation LM lesions with drug-eluting stents (DES). 8 We were able to identify approximately 50 patients reported in the literature who underwent percutaneous treatment for LM trifurcation coronary artery disease. 1 9 LM trifurcation disease is typically treated surgically, particularly when the LM artery is involved, therefore its percutaneous treatment is generally reserved to high-volume centers performing complex coronary interventions. In this study, we report our experience with an additional 52 patients treated with paclitaxel-eluting stents (PES) and present their mid-term outcomes. These were classified according to our previously published classification, 10 allowing testing of the relevance of this classification in a larger series of patients. To our knowledge, this is currently the largest reported experience with LM trifurcation stenting using a PES in the literature with in-hospital and mid-term outcomes described. Methods Fifty-two consecutive patients who underwent LM trifurcation stenting with a PES at our institution from January 1, 2006 to December 31, 2007, were included. Two patients were treated with bare-metal stents during the same period and were excluded. These patients were prospectively identified from a database of patients undergoing cardiac angiography and percutaneous revascularization in the cardiac catheterization laboratory. This retrospective study was approved by the institutional review board at our center. All vessels were qualitatively evaluated by an independent, experienced interventional cardiologist for their size, presence of calcium, number of stents deployed, type of disease (Figure 1A or B), stenting technique used, use of double or triple kissing balloons, preand post-treatment lesion severity, and presence of dissection and embolization or thrombolysis in myocardial infarction Vol. 21, No. 7, July
2 SHAMMAS, et al. Figure 1A. Type A trifurcation disease. (TIMI) flow. The classification of trifurcation disease and treatment methodology have been previously discussed in detail. 10 Procedural success was defined as achieving a residual narrowing of < 30% in all branches treated. The Taxus PES was exclusively used in all patients. Charts were all reviewed for clinical and demographic variables as well as the use of antiplatelet and anticoagulant agents periprocedurally. Dilatation pressures were recorded from the cardiac catheterization laboratory procedure log sheet. Patients with the admission diagnosis of myocardial infarction (MI) were diagnosed by serial cardiac enzymes prior to the procedure. A rapid rise and fall in creatinine kinase with abnormal MB fractions or a typical rise and gradual fall in troponin I with ischemic symptoms or electrocardiographic (ECG) changes was considered diagnostic for acute MI. 11 Unfortunately, post-intervention CK and troponin I were not routinely ordered by the operators, thus the incidence of in-hospital non-q wave MI post procedure cannot be accurately assessed. Only those patients with in-hospital acute ST-elevation MI (STEMI) secondary to acute stent thrombosis could be diagnosed using ECG and enzymatic criteria. The primary endpoint of the study was the combined endpoint of cardiac death, nonfatal MI and target lesion revascularization (TLR) on follow up post hospital discharge. Follow-up data were obtained on 47/51 patients discharged alive (92.2%) from medical records and phone interviews (4 patients were alive and were reached, but refused to provide further information). Secondary endpoints included acute stent thrombosis in-hospital and on follow up and were characterized according to the Academic Research Consortium (ARC) definition: 12 total death, cardiac death, STEMI and non-st-elevation MI (NSTEMI). All events were adjudicated by an independent experienced cardiologist. Descriptive analysis was performed on all variables included. Patients were divided into two groups: those who met the primary endpoint and those who did not. Using univariate analysis, these were compared for all angiographic, clinical and procedural variables. Logistic regression analysis with forward inclusion was also performed and included the following variables: age, gender, lesion Figure 1B. Type B trifurcation disease. type, lesion length, number of stents, pre- and post-treatment lesion severity, diabetes and vessel size. SPSS statistical software was utilized for analysis (SPSS, Inc., Chicago, Illinois). Results Patient demographics are included in Table 1. The procedure was performed urgently in 25.5% of patients. Patients had multiple comorbidities including hypertension (78.8%), diabetes mellitus (32.7%), past or current smoking history (59.2%), hyperlipidemia (86.5%) and prior bypass surgery (17.3%). The mean age was 67.6 ± 12.7 years. The majority of patients were male (75%). The LM artery was unprotected in 88.5% of cases. Approximately two-thirds (60.4%) of patients had stable symptoms on admission, and 39.6% had unstable angina or a NSTEMI. None of the patients admitted had STEMI. The procedure was performed urgently (within hours of presentation) in 25.5% of patients. A summary of angiographic and procedural variables are described in Table 2. Disease involving the trifurcation was classified into two main classes that have been previously published: 10 Type A (30.8%), involving the main trunk with extension to one or more of the origin of the branches; Type B (69.2%), involving the origin of one or more of the main branches without extension to the main trunk (MT). LM trifurcation stenting was classified according to a previously published classification: V-stenting (57.7%) 2. Y-stenting (25%) 3. T-stenting (1.9%) 4. Single-branch stenting (15.4%) The acute procedural success was 100% in all vessels treated, including the main trunk (MT) and side branches (SB). Review of actual angiograms showed no distal embolization, slow-flow or dissections. In-hospital outcomes are described in Table 3. One patient had definite stent thrombosis (ARC definition) post procedure and was retreated successfully. The follow-up duration was ± days. The primary endpoint was met in 16/47 (34%) patients. One out of 322 The Journal of Invasive Cardiology
3 Treatment of Left Main Coronary Trifurcation Lesions Table 1. Demographics and clinical variables. Male (%) 75.0 Age (years) 67.6 ± 12.7 Body mass index 30.7 ± 4.4 Prior coronary artery bypass surgery (%) 17.3 Protected left main (%) 11.5 Previous myocardial infarction (%) 21.2 Family history of coronary disease (%) 60.0 New York Heart Classification (%) Class I 6.1 Class II 24.2 Class III 33.3 Class IV 36.4 Chronic lung disease (%) 21.2 Peripheral vascular disease (%) 15.4 Hypertension (%) 78.8 Cerebrovascular disease (%) 13.5 Diabetes mellitus (%) 32.7 Hyperlipidemia (%) 86.5 Past or current smoker (%) 59.2 Procedure status (%) Elective 74.5 Urgent 25.5 Presentation (%) Stable 60.4 ACS 39.6 All continuous variables are expressed as mean + standard deviation (SD) ACS = acute coronary syndrome the 47 (2.1%) patients suffered sudden cardiac death 5 months after the procedure, with no autopsy performed. The same patient had a possible acute stent thrombosis (ARC definition). He was 47 years of age, hypertensive, nondiabetic, with dyslipidemia and a prior history of smoking. He had a history of a prior MI, but no renal failure or known peripheral arterial disease. He presented with unstable angina and had Type B trifurcation LM disease. The patient was treated with the double V-stenting technique with simultaneous 3-balloon inflations in the trifurcation vessels. He received a total of 4 stents. His left anterior descending artery (LAD) and left circumflex artery (LCx) were treated with 3.5 mm stents and the ramus intermedius with a 2.5 mm stent. Kissing-balloon dilatation of all stents was performed simultaneously at 14 atm. He received heparin, but no glycoprotein (GP) IIb/IIIa inhibitor during the procedure. There was no intravascular ultrasound (IVUS) assessment of the lesions pre- or post treatment. The patient was on clopidogrel and aspirin chronically preprocedure and remained on oral clopidogrel 75 mg daily and oral aspirin 81 mg daily at follow up. It can be speculated that stenting of all trifurcation branches, the long cumulative lesion length (68 mm), and the lack of ultrasound guidance to verify stent apposition and full expansion might have contributed to the possible stent thrombosis. A total of 15/47 (31.9%) patients underwent TLR. Target vessel revascularization (TVR) occurred in 19/47 (40.4%) patients, and no strokes occurred. Prior to the procedure, 83.8% of the patients were on maintenance clopidogrel (75 mg per day). Vol. 21, No. 7, July 2009 Table 2. Summary of procedural and angiographic variables. Type A lesions (involving left main artery) (%) 30.8 Type B lesions (left main not involved) (%) 69.2 Ejection fraction 56.2 ± 15.3 Intravascular ultrasound-guided procedure (%) 0.0 Stenting techniques: V 57.7 Y 25 T 1.9 S 15.4 Simultaneous 3 kissing balloons (%) 38.6 Simultaneous 2 kissing balloons (%) 61.4 No kissing balloon performed (%) 0.0 Mean number of stents used per case 2.9 ± 1.6 Embolization or slow-flow (%) 0.0 Drug-eluting stents (paclitaxel) On chronic clopidogrel use preprocedure (%) 83.8 Loaded with clopidogrel in the cath lab (%) 16.2 Loading dose of 600 mg (%) Anticoagulant during procedure (heparin) Glycoprotein IIb/IIIa inhibitor use (%) 1.9 Side branch 1 (SB1) treatment variables: SB1 size (mm) 2.8 ± 0.3 SB1 restenotic lesions (%) 18.4 SB1 calcified lesion (%) 51.9 SB1 pre-treatment lesion severity (%) 62.8 ± 25.9 SB1 post-treatment lesion severity (%) 2.1 ± 9.0 SB1 Pressure dilatation (mmhg) 14.6 ± 2.2 SB1 number of stents used 1.4 ± 0.8 SB1 stent size used (mm) 3.0 ± 0.3 SB1 stented length (mm) 27.1 ± 19.4 Side branch 2 (SB2) treatment variables: SB2 size (mm) 2.8 ± 0.4 SB2 restenotic lesions (%) 7.5 SB2 calcified lesion (%) 44.2 SB2 pre-treatment lesion severity (%) 64.6 ± 22.6 SB2 post-treatment lesion severity (%) 0.8 ± 3.6 SB2 Pressure dilatation (mmhg) 15.2 ± 3.3 SB2 number of stents used 1.2 ± 0.70 SB2 stent size used (mm) 3.0 ± 0.4 SB2 stented length (mm) 20.7 ± 14.2 Middle branch (MB) treatment variables: MB size (mm) 2.3 ± 0.3 MB restenotic lesions (%) 6.7 MB calcified lesion (%) 38.5 MB pre-treatment lesion severity (%) 70.8 ± 20.4 MB post-treatment lesion severity (%) 1.0 ± 3.7 MB pressure dilatation (mmhg) 14.8 ± 2.3 MB number of stents used 1.0 ± 0.4 MB stent size used (mm) 2.6 ± 0.2 MB stented length (mm) 16.4 ± 9.8 Main trunk (MT) treatment variables: MT size (mm) 4.2 ± 0.4 MT restenotic lesions (%) 0 MT calcified lesion (%) 34.6 MT pre-treatment lesion severity (%) 69.4 ± 21.9 MT post-treatment lesion severity (%) 0.0 ± 0.0 MT pressure dilatation (mmhg) 19.9 ± 3.5 MT number of stents used 0.8 ± 0.4 MT stent size used (mm) 3.4 ± 0.2 MT stented length (mm) 13.6 ± 2.9 LM = left main; SB1 is left anterior descending artery; SB2 is left circumflex; MB is ramus intermedius; MT is left main. All continuous variables are expressed as mean ± standard deviation (SD) 323
4 SHAMMAS, et al. Table 3. In-hospital and out-patient outcomes. In-hospital outcome (n = 52) Renal failure (n = 1) 1.9 Acute closure of successfully treated vessel 0 Distal embolization 0 Vascular access site complication 0 Periprocedural cardiac enzyme elevation meeting ACC definition of Myocardial Infarction* (n = 7) 13.5 Death, noncardiac (n = 1) 1.9 Definite stent thrombosis (ARC definition)** (n = 1) 1.9 Major bleeding 0 Outcome on follow up post discharge (n = 47) Follow-up rate; 1 hospital death censored (n = 47/51) (%) 92.2 Refused consent (n = 4/51) (%) 7.8 Mean follow up (n = 47) (days) ± Target lesion revascularization (n = 15/47) (%) 31.9 Target vessel revascularization (n = 19/47) (%) 40.4 Cardiac death (n = 1/47) (%) 2.1 Death (n = 2/47) (%) 4.3 Acute stent thrombosis (%) Possible (ARC definition) (n = 1/47) 2.1 N-STEMI nonfatal (n = 0/47) (%) 0.0 STEMI nonfatal (n = 1/47) (%) 2.1 Combined endpoint (cardiac death, nonfatal MI and TLR) (n = 16/47) (%) 34.0 ARC = Academic Research Consortium; STEMI = ST-elevation myocardial infarction; TLR = target lesion revascularization; MI = myocardial infarction; ACC = American College of Cardiology The remainder received their clopidogrel load of 600 mg on the day of the procedure. All patients received unfractionated heparin and < 2% of patients received GP IIb/IIIa inhibitors. Univariate analysis showed that the combined endpoint occurred more in patients with type A lesions (56.2% vs. 19.4%; p = 0.02) and with patients that received more stents (3.6 ± 2.0 vs. 2.6 ± 1.4; p = 0.044). Logistic regression analysis with forward inclusion showed that type A lesion (OR 5.33, 95% CI ; p = 0.011) was the only predictor of the occurrence of the primary endpoint. Type A lesion remained the same predictor when TLR was used as the only endpoint (OR 8.1, 95% CI ; p = 0.004). Discussion LM trifurcation lesions are generally treated with bypass surgery. With the advent of DES, complex lesions including LM trifurcation disease, are now treated percutaneously, particularly in patients who refuse or at high risk for bypass. To our knowledge, this is the largest reported series of Taxus PES use in LM trifurcation stenting patients with long-term follow up. In this retrospective series, the primary endpoint of cardiac death, nonfatal MI and TLR occurred in 34% of patients. This was mostly driven by a high TLR rate (31.9%). TVR was 40.4%, similar to a previously reported series, 8 and indicates the rapid progression of native disease in these patients. One patient (1.9%) suffered sudden cardiac death possibly related to stent thrombosis. This is an overall favorable stent thrombosis rate considering that the average number of stents in these patients was 2.9 ± 1.6. This favorable thrombosis rate, despite the minimal use of GP IIb/IIIa inhibitors, is likely related to the use of a high-pressure (14.8 ± 3.2 mmhg) kissing-balloon technique in 84.6% of all patients and in 100% of patients who had > 1 vessel treated (13), as well as the high clopidogrel loading dose (600 mg) prior to the procedure in clopidogrel-naïve patients. In this study, the primary endpoint occurred in a greater number of patients with Type A lesions than Type B lesions (56.2% versus 19.4%; p = 0.02), and in patients who received more stents (3.6 ± 2.0 versus 2.6 ± 1.4; p = 0.044). Diabetes was not an independent predictor of the primary outcome. It is unclear whether this related to the overall small number of patients in the study or whether patients with diabetes have similar outcomes to nondiabetics with the use of the PES. Lesion length, number of stents used and stent length have also been reported to be predictors of major adverse events in highrisk coronary interventions with the use of DES Furthermore, this study validates the previously published classification 10 that separates trifurcation disease with (Type A) or without (Type B) LM disease. A higher adverse event rate is seen in Type A trifurcation lesions, leading one to conclude that a low threshold for surgical intervention rather than percutaneous treatment in these patients may be warranted. Unfortunately in this study, IVUS was not used to assess stent apposition and expansion, and therefore its impact on reducing TLR is unknown. Also, LM stenting was performed with the 3.5 mm Taxus stent that was available to us at the time and was postdilated with a larger balloon. Whether the current 4 mm stent would have also reduced TLR remains unknown. Conclusion In conclusion, trifurcation stenting is technically feasible and offers a high procedural success rate. However, overall adverse events, particularly high rates of TLR and TVR with Type A lesions, are seen. At this time, we continue to recommend that PES stenting to treat trifurcation LM disease be reserved for patients who are at high risk for bypass surgery or refuse surgery. Study limitations. This study is limited by its retrospective design. However, all patients with LM trifurcation disease were included and angiograms were independently reviewed by an experienced angiographer. The mid-term follow up on these patients also exceeded 90%. Also, angiographic restenosis cannot be determined from this study, as no systematic repeat angiography was performed on these patients. In addition, the incidence of patients with trifurcation LM disease who were sent for primary bypass surgery is unknown, and a comparative analysis between those who were treated with bypass versus the PES implantation cannot be made. We do expect, however, as recently seen in the 324 The Journal of Invasive Cardiology
5 Treatment of Left Main Coronary Trifurcation Lesions the SYNergy between percutaneous coronary intervention with TAXus and cardiac surgery (SYNTAX) study that a higher TLR rate will be seen with DES treatment compared to bypass surgery. Although the overall rate of repeat revascularization (13.5%) in SYNTAX appears significantly less than our TLR rate, SYNTAX included mostly bifurcation lesions and, to a lesser extent, trifurcation LM lesions. In our study, all patients had trifurcation lesions, more complex anatomy requiring more stents and longer overall treated lesion lengths. Finally, this study does not address the role of provisional stenting in trifurcation LM disease, an area that requires further study. References 1. Lindsey RL Jr, Saporito J, Kleist PC, Kalash Y. Triple balloon-on-a-wire or menage à trois coronary angioplasty. Cathet Cardiovasc Diagn 1993;28: Colombo A. Case Studies 2002 October 2002 LMCA trifurcation stenosis treated with Cypher stents and GP IIb/IIIa inhibitor with subsequent acute LAD occlusion and repeat intervention. Presented at TCTMD.com 3. Colombo A. Case Studies 2001 Trifurcation stenting using rapamycin-coated stents with follow-up. Presented at TCTMD.com 4. Hong M-K, Marchment J. Case Studies 2004 July 2004 Left anterior descending trifurcation lesion treated with three Taxus stents. Presented at TCTMD.com 5. Chieffo A, Stankovic G, Bonizzoni E, et al. Early and mid-term results of drug-eluting stent implantation in unprotected left main. Circulation 2005;111: Shammas NW, Dippel EJ, Avila A, et al. Long-term outcomes in treating left main trifurcation coronary artery disease with the paclitaxel-eluting stent. J Invasive Cardiol 2007;19: Anselmino M, Biondi-Zoccai G, Moretti C, Sheiban I. Percutaneous coronary intervention on left main coronary artery trifurcation. Heart Vessels 2008;23: Furuichi S, Sangiorgi GM, Palloshi A, et al. Drug-eluting stent implantation in coronary trifurcation lesions. J Invasive Cardiol 2007;19: Alizadehranjbar K, Brass N, Cheung P, et al. Successful treatment of trifurcation and quadrifurcation lesions using a minimal protrusion balloon crush technique. J Interv Cardiol 2008;21: Shammas NW. Trifurcation coronary artery disease: A proposed classification and treatment methodology. J Invasive Cardiol 2007;19: The Joint European Society of Cardiology/American College of Cardiology Committee. Myocardial infarction redefined A consensus document of the the Joint European Society of Cardiology/American College of Cardiology Committee for the Redefinition of Myocardial Infarction. Eur Heart J 2000;21: Serruys PW, Daemen J. Late stent thrombosis: A nuisance in both bare metal and drug-eluting stents. Circulation 2007;115: Colombo A, Moses JW, Morice MC, et al. Randomized study to evaluate sirolimuseluting stents implanted at coronary bifurcation lesions. Circulation 2004;109: Azzarelli S, Amico F, Galassi AR, et al. Two-year clinical follow up of coronary drugeluting stent in patients at high risk for coronary restenosis. J Invasive Cardiol 2008;20: Stone GW, Ellis SG, Cannon L, et al. Comparison of a polymer-based paclitaxeleluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial. JAMA 2005;294: Lemos PA, Hoye A, Goedhart D, et al. Clinical, angiographic, and procedural predictors of angiographic restenosis after sirolimus-eluting stent implantation in complex patients: An evaluation from the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) study. Circulation 2004;109: Abizaid A, Chan C, Lim YT, et al. Twelve-month outcomes with a paclitaxel-eluting stent transitioning from controlled trials to clinical practice (the WISDOM registry). Am J Cardiol 2006;98: Sharis PJ, Voelliger CM, Ahuja A, et al. Large single center experience with unprotected left main coronary artery drug-eluting stenting in 289 patients. Presented at New Cardiovascular Horizons, September 2008, abstract #2, New Orleans, Louisianna. 19. Mohr EF. SYNTAX trial end points in 3VD subset. TCT 2008; October 14, 2008; Washington, D.C 20. Serruys P. SYNTAX trial end points in left main subset. TCT 2008; October 14, 2008; Washington, D.C. Vol. 21, No. 7, July
Clinical Study Age Differences in Long Term Outcomes of Coronary Patients Treated with Drug Eluting Stents at a Tertiary Medical Center
Aging Research Volume 2013, Article ID 471026, 4 pages http://dx.doi.org/10.1155/2013/471026 Clinical Study Age Differences in Long Term Outcomes of Coronary Patients Treated with Drug Eluting Stents at
More informationLM stenting - Cypher
LM stenting - Cypher Left main stenting with BMS Since 1995 Issues in BMS era AMC Restenosis and TLR (%) 3 27 TLR P=.282 Restenosis P=.71 28 2 1 15 12 Ostium 5 4 Shaft Bifurcation Left main stenting with
More informationISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions
Julinda Mehilli, MD Deutsches Herzzentrum Technische Universität Munich Germany ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions Background Left main
More informationPROMUS Element Experience In AMC
Promus Element Luncheon Symposium: PROMUS Element Experience In AMC Jung-Min Ahn, MD. University of Ulsan College of Medicine, Heart Institute, Asan Medical Center, Seoul, Korea PROMUS Element Clinical
More informationThe MAIN-COMPARE Study
Long-Term Outcomes of Coronary Stent Implantation versus Bypass Surgery for the Treatment of Unprotected Left Main Coronary Artery Disease Revascularization for Unprotected Left MAIN Coronary Artery Stenosis:
More informationAbstract Background: Methods: Results: Conclusions:
Two-Year Clinical and Angiographic Outcomes of Overlapping Sirolimusversus Paclitaxel- Eluting Stents in the Treatment of Diffuse Long Coronary Lesions Kang-Yin Chen 1,2, Seung-Woon Rha 1, Yong-Jian Li
More informationPeriprocedural Myocardial Infarction and Clinical Outcome In Bifurcation Lesion
Periprocedural Myocardial Infarction and Clinical Outcome In Bifurcation Lesion Hyeon-Cheol Gwon Cardiac and Vascular Center Samsung Medical Center Sungkyunkwan University School of Medicine Dr. Hyeon-Cheol
More informationUnprotected LM intervention
Unprotected LM intervention Guideline for COMBAT Seung-Jung Park, MD, PhD Professor of Internal Medicine, Seoul, Korea Current Recommendation for unprotected LMCA Stenosis Class IIb C in ESC guideline
More informationJournal of the American College of Cardiology Vol. 46, No. 5, by the American College of Cardiology Foundation ISSN /05/$30.
Journal of the American College of Cardiology Vol. 46, No. 5, 2005 2005 by the American College of Cardiology Foundation ISSN 0735-1097/05/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2005.06.009
More informationKurdistan Technique for the Treatment of Unprotected Trifurcation Left Main Stem Coronary Artery Lesion: Case Report
World Journal of Cardiovascular Diseases, 2014, 4, 483-491 Published Online August 2014 in SciRes. http://www.scirp.org/journal/wjcd http://dx.doi.org/10.4236/wjcd.2014.49058 Kurdistan Technique for the
More informationClinical Investigations
Clinical Investigations Clinical Outcomes for Single Stent and Multiple Stents in Contemporary Practice Qiao Shu Bin, MD; Liu Sheng Wen, MD; Xu Bo, BS; Chen Jue, MD; Liu Hai Bo, MD; Yang Yue Jin, MD; Chen
More informationTCTAP Upendra Kaul MD,DM,FACC,FSCAI,FAMS,FCSI
Indian TUXEDO Trial In Medically Treated Diabetics Upendra Kaul MD,DM,FACC,FSCAI,FAMS,FCSI Executive Director and Dean Escorts Heart Institute & Medical Research Center and Fortis Hospitals, New Delhi
More informationSupplementary Material to Mayer et al. A comparative cohort study on personalised
Suppl. Table : Baseline characteristics of the patients. Characteristic Modified cohort Non-modified cohort P value (n=00) Age years 68. ±. 69.5 ±. 0. Female sex no. (%) 60 (0.0) 88 (.7) 0.0 Body Mass
More informationRationale for Percutaneous Revascularization ESC 2011
Rationale for Percutaneous Revascularization Marie Claude Morice, Massy FR MD, FESC, FACC ESC 2011 Paris Villepinte - 27-31 August, 2011 Massy, France Potential conflicts of interest I have the following
More informationLessons learned From The National PCI Registry
Lessons learned From The National PCI Registry w a v e On Behalf of The Publication Committee of the National PCI Registry Objectives & Anticipated Achievements To determine the epidemiology of patients
More informationPerspective of LM stenting with Current registry and Randomized Clinical Data
Asian Pacific TCT Perspective of LM stenting with Current registry and Randomized Clinical Data Patrick W. Serruys MD PhD Yoshinobu Onuma MD Seung-Jung Park MD, PhD 14:48-15:00, 2009 Symposium Arena, Level
More informationResolute in Bifurcation Lesions: Data from the RESOLUTE Clinical Program
Resolute in Bifurcation Lesions: Data from the RESOLUTE Clinical Program Prof. Ran Kornowski, MD, FESC, FACC Director - Division of Interventional Cardiology Rabin Medical Center and Tel Aviv University,
More informationEffect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial
Effect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial Myeong-Ki Hong, MD. PhD on behalf of the IVUS-XPL trial investigators
More informationCase Report Left Main Stenosis. Percutaneous Coronary Intervention (PCI) or Coronary Artery Bypass Graft Surgery (CABG)?
Cronicon OPEN ACCESS CARDIOLOGY Case Report Left Main Stenosis. Percutaneous Coronary Intervention (PCI) or Coronary Artery Bypass Graft Surgery (CABG)? Valentin Hristov* Department of Cardiology, Specialized
More informationEXCEL vs. NOBLE: How to Treat Left Main Disease in 2017 AATS International Cardiovascular Symposium December 8-9, 2017
EXCEL vs. NOBLE: How to Treat Left Main Disease in 2017 AATS International Cardiovascular Symposium December 8-9, 2017 Igor F. Palacios, MD Director of Interventional Cardiology Professor of Medicine Massachusetts
More informationPCI for LMCA lesions A Review of latest guidelines and relevant evidence
HCS Working Group Seminars Met Hotel, Thursday 14 th February 2013 PCI for LMCA lesions A Review of latest guidelines and relevant evidence Vassilis Spanos Interventional Cardiologist, As. Director 3 rd
More informationOne-Year Outcomes After Everolimus-Eluting Stents Implantation in Ostial Lesions of Left Anterior Descending Coronary Arteries
Elmer Press Original Article One-Year Outcomes After Everolimus-Eluting Stents Implantation in Ostial Lesions of Left Anterior Descending Coronary Arteries Zahra Golmohamadi a, c, Sepideh Sokhanvar b,
More informationSupplementary Online Content
Supplementary Online Content Valle JA, Tamez H, Abbott JD, et al. Contemporary use and trends in unprotected left main coronary artery percutaneous coronary intervention in the United States: an analysis
More informationStent Thrombosis in Bifurcation Stenting
Summit TCT Asia Pacific 2009 Stent Thrombosis in Bifurcation Stenting Associate Professor Tan Huay Cheem MBBS, M Med(Int Med), MRCP, FRCP(UK), FAMS, FACC, FSCAI Director, National University Heart Centre,
More informationLeft Main and Bifurcation Summit I. Lessons from European LM Studies
Left Main and Bifurcation Summit I Apr 29 8.56-9.09 Lessons from European LM Studies Alaide Chieffo, MD S. Raffaele Hospital, Milan, Italy Nothing to disclose regarding this presentation Lesion Location
More informationJournal of the American College of Cardiology Vol. 47, No. 7, by the American College of Cardiology Foundation ISSN /06/$32.
Journal of the American College of Cardiology Vol. 47, No. 7, 2006 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2005.05.102
More informationLe# main treatment with Stentys stent. Carlo Briguori, MD, PhD Clinica Mediterranea Naples, Italy
Le# main treatment with Stentys stent Carlo Briguori, MD, PhD Clinica Mediterranea Naples, Italy Disclosure Statement of Financial Interest I, Carlo Briguori DO NOT have a financial interest/ arrangement
More informationPercutaneous Intervention of Unprotected Left Main Disease
Percutaneous Intervention of Unprotected Left Main Disease Technical feasibility and Clinical outcomes Seung-Jung Park, MD, PhD, FACC Professor of Internal Medicine Asan Medical Center, Seoul, Korea Unprotected
More informationBifurcation stenting with BVS
Bifurcation stenting with BVS Breaking the limits or just breaking the struts? Maciej Lesiak Department of Cardiology University Hospital in Poznan, Poland Disclosure Speaker s name: Maciej Lesiak I have
More informationWhat is the Optimal Triple Anti-platelet Therapy Duration in Patients with Acute Myocardial Infarction Undergoing Drug-eluting Stents Implantation?
What is the Optimal Triple Anti-platelet Therapy Duration in Patients with Acute Myocardial Infarction Undergoing Drug-eluting Stents Implantation? Keun-Ho Park, Myung Ho Jeong, Min Goo Lee, Jum Suk Ko,
More informationPercutaneous Coronary Interventions Without On-site Cardiac Surgery
Percutaneous Coronary Interventions Without On-site Cardiac Surgery Hassan Al Zammar, MD,FESC Consultant & Interventional Cardiologist Head of Cardiology Department European Gaza Hospital Palestine European
More informationFormation of and countermeasures for subacute coronary stent thrombosis in elderly diabetic patients
Formation of and countermeasures for subacute coronary stent thrombosis in elderly diabetic patients Z.-F. Li 1, Y.-P. Zhang 2, Z.-Q. Qin 2, X.-L. Li 1, C.-H. Gao 1, S. Yang 1 and Z.-J. Chen 1 1 Department
More informationLesions at coronary bifurcations represent a challenging
Randomized Study to Evaluate Sirolimus-Eluting Stents Implanted at Coronary Bifurcation Lesions Antonio Colombo, MD; Jeffrey W. Moses, MD; Marie Claude Morice, MD; Josef Ludwig, MD; David R. Holmes, Jr,
More informationUnprotected Left Main Coronary Artery Disease in Patients With Low Predictive Risk of Mortality
Unprotected Left Main Coronary Artery Disease in Patients With Low Predictive Risk of Mortality Shun Watanabe, MD, Tatsuhiko Komiya, MD, Genichi Sakaguchi, MD, PhD, and Takeshi Shimamoto, MD, PhD Department
More informationSupplementary Table S1: Proportion of missing values presents in the original dataset
Supplementary Table S1: Proportion of missing values presents in the original dataset Variable Included (%) Missing (%) Age 89067 (100.0) 0 (0.0) Gender 89067 (100.0) 0 (0.0) Smoking status 80706 (90.6)
More informationStent Thrombosis: Patient, Procedural, and Stent Factors. Eugene Mc Fadden Cork, Ireland
Stent Thrombosis: Patient, Procedural, and Stent Factors Eugene Mc Fadden Cork, Ireland Definitions Early 1 yr TAXUS >6months CYPHER Incidence and Timing BMS Registry data
More informationUnprotected Left Main Stenting: Patient Selection and Recent Experience. Alaide Chieffo. S. Raffaele Hospital, Milan, Italy
Unprotected Left Main Stenting: Patient Selection and Recent Experience Alaide Chieffo S. Raffaele Hospital, Milan, Italy Class IIa (Level B) AHA/ACC 2005 Guidelines Left Main CAD The use of PCI for pts
More informationJournal of the American College of Cardiology Vol. 57, No. 12, by the American College of Cardiology Foundation ISSN /$36.
Journal of the American College of Cardiology Vol. 57, No. 12, 2011 2011 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2010.10.041
More informationSTENTYS for Le, Main Sten2ng. Carlo Briguori, MD, PhD Clinica Mediterranea Naples, Italy
STENTYS for Le, Main Sten2ng Carlo Briguori, MD, PhD Clinica Mediterranea Naples, Italy Disclosure Statement of Financial Interest I, Carlo Briguori DO NOT have a financial interest/ arrangement or affilia2on
More informationChapter 29 Left Main Intervention in the Light of EXCEL and NOBLE Trials
Chapter 29 Left Main Intervention in the Light of EXCEL and NOBLE Trials DEBDATTA BHATTACHARYYA AYAN KAR The incidence of angiographically significant left main stenosis described in various studies has
More informationThe MAIN-COMPARE Registry
Long-Term Outcomes of Coronary Stent Implantation versus Bypass Surgery for the Treatment of Unprotected Left Main Coronary Artery Disease Revascularization for Unprotected Left MAIN Coronary Artery Stenosis:
More informationPost PCI functional testing and imaging: case based lessons from FFR React
Post PCI functional testing and imaging: case based lessons from FFR React Joost Daemen, MD, PhD, FESC Optics in Cardiology 2018 April 21st, 2018 10.15 10.30h Disclosure Statement of Financial Interest
More informationWhat oral antiplatelet therapy would you choose? a) ASA alone b) ASA + Clopidogrel c) ASA + Prasugrel d) ASA + Ticagrelor
76 year old female Prior Hypertension, Hyperlipidemia, Smoking On Hydrochlorothiazide, Atorvastatin New onset chest discomfort; 2 episodes in past 24 hours Heart rate 122/min; BP 170/92 mm Hg, Killip Class
More informationA Large Prospective Randomized Trial of DES vs BMS in Patients with STEMI
HORIZONS-AMI: A Large Prospective Randomized Trial of DES vs BMS in Patients with STEMI Gregg W. Stone MD Columbia University Medical Center Cardiovascular Research Foundation Disclosures Gregg W. Stone
More informationJournal of the American College of Cardiology Vol. 47, No. 8, by the American College of Cardiology Foundation ISSN /06/$32.
Journal of the American College of Cardiology Vol. 47, No. 8, 2006 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2005.11.066
More informationCount Down to COMBAT
Count Down to COMBAT Randomized COMparison of Bypass Surgery versus AngioplasTy using Sirolimus-Eluting Stent in Patients with Left Main Coronary Artery Disease Roxana Mehran, MD Associate Professor of
More informationSide Branch Occlusion
Side Branch Occlusion Mechanism, Outcome, and How to avoid it From COBIS II Registry Hyeon-Cheol Gwon Cardiac&Vascular Center, Samsung Medical Center Sungkyunkwan University School of Medicine SB occlusion
More informationPCI for Left Main Coronary Artery Stenosis. Jean Fajadet Clinique Pasteur, Toulouse, France
PCI for Left Main Coronary Artery Stenosis Jean Fajadet Clinique Pasteur, Toulouse, France Athens, October 19, 2018 Left Main Coronary Artery Disease Significant unprotected left main coronary artery disease
More information2010 Korean Society of Cardiology Spring Scientific Session Korea Japan Joint Symposium. Seoul National University Hospital Cardiovascular Center
2010 Korean Society of Cardiology Spring Scientific Session Korea Japan Joint Symposium Does Lt Late Cth Catch up Exist Eiti in DES? : Quantitative Coronary Angiography Analysis Kyung Woo Park, MD Cardiovascular
More informationTechnical considerations in the Treatment of Left Main Lesions Ioannis Iakovou, MD, PhD
Technical considerations in the Treatment of Left Main Lesions Ioannis Iakovou, MD, PhD Onassis Cardiac Surgery Center, Athens, Greece Critical issues in LM PCI Anatomic variability Techniques Variability
More informationAPPENDIX F: CASE REPORT FORM
APPENDIX F: CASE REPORT FORM Instruction: Complete this form to notify all ACS admissions at your centre to National Cardiovascular Disease Registry. Where check boxes are provided, check ( ) one or more
More informationPCI for Long Coronary Lesion
PCI for Long Coronary Lesion Shift of a General Idea with the Introduction of DES In the Bare Metal Stent Era Higher Restenosis Rate With Increasing Stent Length and Decreasing Stent Area Restenosis.6.4.2
More informationHCS Working Group Seminars Macedonia Pallas Hotel, Friday 21 st February Drug-eluting stents Are they all equal?
HCS Working Group Seminars Macedonia Pallas Hotel, Friday 21 st February 2014 Drug-eluting stents Are they all equal? Vassilis Spanos Interventional Cardiologist, As. Director 3 rd Cardiology Clinic Euroclinic
More informationIntra-Procedural Stent Thrombosis
JACC: CARDIOVASCULAR INTERVENTIONS VOL. 6, NO. 1, 2013 2013 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 1936-8798/$36.00 PUBLISHED BY ELSEVIER INC. http://dx.doi.org/10.1016/j.jcin.2012.08.018
More information388-1 Poongnap-dong, Songpa-gu, Seoul, , Republic of Korea b Department of Medicine, Changi General Hospital, Singapore
International Journal of Cardiology 126 (2008) 224 228 www.elsevier.com/locate/ijcard Percutaneous coronary intervention with stenting of left main coronary artery with drug-eluting stent in the setting
More informationDrug Eluting Stents Sometimes Fail ESC Stockholm 29 Set 2010 Stent Thrombosis Alaide Chieffo
Drug Eluting Stents Sometimes Fail ESC Stockholm 29 Set 2010 Stent Thrombosis 11.45-12.07 Alaide Chieffo San Raffaele Scientific Institute, Milan, Italy Historical Perspective 25 20 15 10 5 0 Serruys 1991
More informationPCI for In-Stent Restenosis. CardioVascular Research Foundation
PCI for In-Stent Restenosis ISR of BMS Patterns of In-Stent Restenosis Pattern I : Focal Type IA: Articulation / Gap Type IB: Marginal Type IC: Focal body Type ID: Multifocal Pattern II,III,IV : Diffuse
More informationLong-term outcomes of PCI vs. CABG for ostial/midshaft lesions in unprotected left main coronary artery
Journal of Geriatric Cardiology (2017) 14: 254 260 2017 JGC All rights reserved; www.jgc301.com Research Article Open Access Long-term outcomes of PCI vs. CABG for ostial/midshaft lesions in unprotected
More informationTarget vessel only revascularization versus complet revascularization in non culprit lesions in acute myocardial infarction treated by primary PCI
Target vessel only revascularization versus complet revascularization in non culprit lesions in acute myocardial infarction treated by primary PCI Gamal Abdelhady, Emad Mahmoud Department of interventional
More informationUpgrade of Recommendation
Challenges in LM PCI Decision-making process for stenting Young-Hak Kim, MD, PhD, Heart Institute, University of Ulsan College of Medicine Asan Medical Center, Seoul, Korea Upgrade of Recommendation for
More informationGender-Based Outcomes in Percutaneous Coronary Intervention with Drug-Eluting Stents (from the National Heart, Lung, and Blood Institute Dynamic
Gender-Based Outcomes in Percutaneous Coronary Intervention with Drug-Eluting Stents (from the National Heart, Lung, and Blood Institute Dynamic Registry) J. D. Abbott, et al. Am J Cardiol (2007) 99;626-31
More informationImportant LM bifurcation studies update
8 th European Bifurcation Club 12-13 October 2012 - Barcelona Important LM bifurcation studies update I Sheiban E-mail: isheiban@yahoo.com Unprotected LM Percutaneous Revascularization What is important
More informationCase Report Primary Percutaneous Coronary Intervention in an Acute Myocardial Infarction Due to the Occlusion of the Left Main Coronary Artery
Hellenic J Cardiol 48: 368-372, 2007 Case Report Primary Percutaneous Coronary Intervention in an Acute Myocardial Infarction Due to the Occlusion of the Left Main Coronary Artery STELIOS PARASKEVAIDIS,
More informationFor Personal Use. Copyright HMP 2014
Original Contribution Long-Term Safety and Efficacy of the Everolimus-Eluting Stent Compared to First-Generation Drug-Eluting Stents in Contemporary Clinical Practice Israel M. Barbash, MD, Sa ar Minha,
More informationJournal of the American College of Cardiology Vol. 48, No. 2, by the American College of Cardiology Foundation ISSN /06/$32.
Journal of the American College of Cardiology Vol. 48, No. 2, 2006 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2006.03.039
More informationin an Unyielding Patient Dr Jason See, Dr Goh Yew Seong, Dr Rohit Khurana Changi General Hospital Singapore
Unrelenting Left Main Disease in an Unyielding Patient Dr Jason See, Dr Goh Yew Seong, Dr Rohit Khurana Changi General Hospital Singapore Clinical History 72 years old Chinese lady Background and CV Risk
More informationTRIAS HR Pilot Study
Late Breaking Clinical Trials TCT, October 22 nd 27, Washington, USA TRIAS HR Pilot Study RCT comparing Genous EPC capturing stent with Taxus Paclitaxel eluting stent Robbert J de Winter MD PhD FESC Academic
More informationNew Generation Drug- Eluting Stent in Korea
New Generation Drug- Eluting Stent in Korea Young-Hak Kim, MD, PhD Department of Cardiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea Purpose To briefly introduce the
More informationARMYDA-RECAPTURE (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) trial
ARMYDA-RECAPTURE ( for Reduction of MYocardial Damage during Angioplasty) trial Prospective, multicenter, randomized, double blind trial investigating efficacy of atorvastatin reload in patients on chronic
More informationSeptember Peter Barlis. Royal Brompton Hospital, London, UK
3rd EBC Meeting European Bifurcation Club September 2007 PALAU DE LA MUSICA, SalaRodrigo VALENCIA, SPAIN Culotte Technique in Left Main Disease Peter Barlis Carlo DiMario Royal Brompton Hospital, London,
More informationLong-term freedom from angina and
Hellenic J Cardiol 2010; 51: 368-373 Case Report The Crush Technique as a Therapeutic Approach for a Bifurcation Lesion in a Saphenous Venous Graft Io a n n i s Ka r a l i s, Ge o r g e Ko c h i a d a
More informationFFR-guided Jailed Side Branch Intervention
FFR-guided Jailed Side Branch Intervention - Pressure wire in Bifurcation lesions - Bon-Kwon Koo, MD, PhD Seoul National University Hospital, Seoul, Korea Bifurcation Lesions Bifurcation Lesions Still
More informationSafety of Single- Versus Multi-vessel Angioplasty for Patients with AMI and Multi-vessel CAD
Safety of Single- Versus Multi-vessel Angioplasty for Patients with AMI and Multi-vessel CAD Mun K. Hong, MD Associate Professor of Medicine Director, Cardiovascular Intervention and Research Weill Cornell
More informationCoronary drug-eluting stents (DES) were first approved
Thrombosis in Coronary Drug-Eluting Stents Report From the Meeting of the Circulatory System Medical Devices Advisory Panel of the Food and Drug Administration Center for Devices and Radiologic Health,
More informationeucalimus - First Experience
A New Sirolimus Eluting Stent with a Biodegradable Polymer Early and Mid Term Experience with the eucalimus Stent in Egypt Dr. Hossam El Din Mohamed Mansour on behalf of the investigators Ahmed Emara,
More informationNon-LM bifurcation studies of importance in 2011
7th European Bifurcation Club 14-15 October 2011 LISBON Goran Stankovic MD, PhD Non-LM bifurcation studies of importance in 2011 October 15 th : 08:00 08:10 DKCRUSH-II: A Prospective Randomized Trial of
More informationDEB experience in Gachon Universtiy Gil Hospital (in ISR) Soon Yong Suh MD., PhD. Heart Center Gachon University Gil Hospital Seoul, Korea.
DEB experience in Gachon Universtiy Gil Hospital (in ISR) Soon Yong Suh MD., PhD. Heart Center Gachon University Gil Hospital Seoul, Korea. In-stent restenosis (ISR) Remains important issue even in the
More informationLeft Main Intervention: Will it become standard of care?
Left Main Intervention: Will it become standard of care? David Cox, MD FSCAI, FACC Director, Interventional Cardiology Research Associate Director, Cardiac Cath Lab Lehigh Valley Health Network Allentown,
More informationFor Personal Use. Copyright HMP 2013
Case Report J INVASIVE CARDIOL 2013;25(2):E39-E41 A Case With Successful Retrograde Stent Delivery via AC Branch for Tortuous Right Coronary Artery Yoshiki Uehara, MD, PhD, Mitsuyuki Shimizu, MD, PhD,
More informationClopidogrel Date: 15 July 2008
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: sanofi-aventis ClinicalTrials.gov
More informationNine-year clinical outcomes of drug-eluting stents vs. bare metal stents for large coronary vessel lesions
Journal of Geriatric Cardiology (2017) 14: 35 41 2017 JGC All rights reserved; www.jgc301.com Research Article Open Access Nine-year clinical outcomes of drug-eluting stents vs. bare metal stents for large
More informationKomplexe Koronarintervention heute: Von Syntax zu bioresorbierbaren Stents
Komplexe Koronarintervention heute: Von Syntax zu bioresorbierbaren Stents Prof. Dr. med. Julinda Mehilli Medizinische Klinik und Poliklinik I Klinikum der Universität München Campus Großhadern Key Factors
More informationRCA Disease and Unprotected LM Stenting
Original Article RCA Disease and Unprotected LM Stenting Acta Cardiol Sin 2011;27:14 20 Coronary Heart Disease The Clinical Significance of Right Coronary Artery Stenosis on the Prognosis of Patients with
More informationBern-Rotterdam Cohort Study
Bern-Rotterdam Cohort Study Newer generation everolimus-eluting stents eliminate the risk of very late stent thrombosis compared with early generation sirolimus-eluting and paclitaxel-eluting stents Lorenz
More informationC. W. Hamm, B. Cremers, H. Moellmann, S. Möbius-Winkler, U. Zeymer, M. Vrolix, S. Schneider, U. Dietz, M. Böhm, B. Scheller
Paclitaxel-Eluting PTCA-Balloon in Combination with the Coroflex Blue Stent vs the Sirolimus Coated Cypher Stent in the Treatment of Advanced Coronary Artery Disease C. W. Hamm, B. Cremers, H. Moellmann,
More informationCOMBAT- Revised Protocol
COMBAT- Revised Protocol Randomized COMparison of Bypass Surgery versus AngioplasTy using Sirolimus-Eluting Stent in Patients with Left Main Coronary Artery Disease Roxana Mehran, MD Associate Professor
More informationeluting Stents The SPIRIT Trials
Everolimus-eluting eluting Stents The SPIRIT Trials Gregg W. Stone, MD Columbia University Medical Center Cardiovascular Research Foundation Abbott XIENCE V Everolimus-eluting eluting Stent Everolimus
More informationCulprit Lesion Remodeling and Long-term (> 5years) Prognosis in Patients with Acute Coronary Syndrome
Culprit Lesion Remodeling and Long-term (> 5years) Prognosis in Patients with Acute Coronary Syndrome Hiroyuki Okura*, MD; Nobuya Matsushita**,MD Kenji Shimeno**, MD; Hiroyuki Yamaghishi**, MD Iku Toda**,
More informationClinical Study Everolimus-Eluting versus Paclitaxel-Eluting Stents in Percutaneous Coronary Intervention: Meta-Analysis of Randomized Trials
Thrombosis Volume 2012, Article ID 126369, 8 pages doi:10.1155/2012/126369 Clinical Study Everolimus-Eluting versus Paclitaxel-Eluting Stents in Percutaneous Coronary Intervention: Meta-Analysis of Randomized
More informationSurgical vs. Percutaneous Revascularization in Patients with Diabetes and Acute Coronary Syndrome
Surgical vs. Percutaneous Revascularization in Patients with Diabetes and Acute Coronary Syndrome Chris C. Cook, MD Associate Professor of Surgery Director, CT Residency Program, WVU ACOI 10/17/18 No Disclosures
More informationCoronary Artery Disease: Revascularization (Teacher s Guide)
Stephanie Chan, M.D. Updated 3/15/13 2008-2013, SCVMC (40 minutes) I. Objectives Coronary Artery Disease: Revascularization (Teacher s Guide) To review the evidence on whether percutaneous coronary intervention
More informationManagement of restenosis after drug-eluting stent placement for unprotected left main disease
Review Management of restenosis after drug-eluting stent placement for unprotected left main disease In some institutions a percutaneous approach to unprotected left main (ULM) disease has become a valid
More informationThe SYNTAX-LE MANS Study
The SYNTAX-LE MANS Study Synergy Between PCI with TAXUS Express and Cardiac Surgery: Late (15-month) Left Main Angiographic Substudy A. Pieter Kappetein, MD, PhD Erasmus MC, Rotterdam, NL SYNTAX-LE MANS
More informationPrevention of Coronary Stent Thrombosis and Restenosis
Prevention of Coronary Stent Thrombosis and Restenosis Seong-Wook Park, MD, PhD, FACC Division of Cardiology, Asan Medical Center University of Ulsan College of Medicine, Seoul, Korea 9/12/03 Coronary
More informationEBC London 2013 Provisional SB stenting strategy with kissing balloon with Absorb
EBC London 2013 Provisional SB stenting strategy with kissing balloon with Absorb A. Medina Servicio de Cardiología Hospital Universitario de Gran Canaria Dr. Negrín Islas Canarias (Spain) Provisional
More informationANGIOPLASY SUMMIT 2007 TCT ASIA PACIFIC. Seoul, Korea: April Session: Left mains & bifurcation intervention
ANGIOPLASY SUMMIT 2007 TCT ASIA PACIFIC Seoul, Korea: 25-27 27 April 2007 Session: Left mains & bifurcation intervention An integrated approach to bifurcation lesions: lessons from years of randomized
More informationFor Personal Use. Copyright HMP 2013
Original Contribution Impact of Technique and Bifurcation Anatomy on Long-Term Outcomes of PCI for Distal Unprotected Left Main Coronary Disease William Ng, MBBS 1, Robert Lundstrom, MD 1, Edward McNulty,
More informationPaclitaxel-Eluting Coronary Stents in Patients With Diabetes Mellitus
Journal of the American College of Cardiology Vol. 51, No. 7, 2008 2008 by the American College of Cardiology Foundation ISSN 0735-1097/08/$34.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2007.10.035
More informationSunao Nakamura M.D,Ph.D.
Drug Eluting Stent Implantation For Unprotected Left ain Coronary Arteries New Tokyo Circulation Research Group New Tokyo Hospital Sunao Nakamura.D,Ph.D. Drug-Eluting Stent for Left ain Coronary Artery
More informationJournal of the American College of Cardiology Vol. 55, No. 9, by the American College of Cardiology Foundation ISSN /10/$36.
Journal of the American College of Cardiology Vol. 55, No. 9, 2010 2010 by the American College of Cardiology Foundation ISSN 0735-1097/10/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2009.09.052
More information